AU2018316662A1 - Method - Google Patents

Method Download PDF

Info

Publication number
AU2018316662A1
AU2018316662A1 AU2018316662A AU2018316662A AU2018316662A1 AU 2018316662 A1 AU2018316662 A1 AU 2018316662A1 AU 2018316662 A AU2018316662 A AU 2018316662A AU 2018316662 A AU2018316662 A AU 2018316662A AU 2018316662 A1 AU2018316662 A1 AU 2018316662A1
Authority
AU
Australia
Prior art keywords
peptide
subject
disease
seq
myelin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018316662A
Other languages
English (en)
Inventor
Liselotta JANSSON
Keith Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worg Pharmaceuticals Zhejiang Co Ltd
Original Assignee
Worg Pharmaceuticals Zhejiang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713036.0A external-priority patent/GB201713036D0/en
Priority claimed from GBGB1713037.8A external-priority patent/GB201713037D0/en
Priority claimed from GBGB1713035.2A external-priority patent/GB201713035D0/en
Application filed by Worg Pharmaceuticals Zhejiang Co Ltd filed Critical Worg Pharmaceuticals Zhejiang Co Ltd
Publication of AU2018316662A1 publication Critical patent/AU2018316662A1/en
Assigned to Wong Pharmaceuticals (Hangzhou) Co., Ltd. reassignment Wong Pharmaceuticals (Hangzhou) Co., Ltd. Request for Assignment Assignors: APITOPE TECHNOLOGY (BRISTOL) LIMITED
Assigned to Worg Pharmaceuticals (Hangzhou) Co., Ltd. reassignment Worg Pharmaceuticals (Hangzhou) Co., Ltd. Amend patent request/document other than specification (104) Assignors: Wong Pharmaceuticals (Hangzhou) Co., Ltd.
Assigned to Worg Pharmaceuticals (Zhejiang) Co., Ltd. reassignment Worg Pharmaceuticals (Zhejiang) Co., Ltd. Amend patent request/document other than specification (104) Assignors: Worg Pharmaceuticals (Hangzhou) Co., Ltd.
Priority to AU2025201115A priority Critical patent/AU2025201115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2018316662A 2017-08-14 2018-08-14 Method Abandoned AU2018316662A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201115A AU2025201115A1 (en) 2017-08-14 2025-02-17 Method

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1713036.0A GB201713036D0 (en) 2017-08-14 2017-08-14 Method
GBGB1713037.8A GB201713037D0 (en) 2017-08-14 2017-08-14 Method
GB1713036.0 2017-08-14
GB1713035.2 2017-08-14
GB1713037.8 2017-08-14
GBGB1713035.2A GB201713035D0 (en) 2017-08-14 2017-08-14 Method
PCT/GB2018/052304 WO2019034862A1 (en) 2017-08-14 2018-08-14 Method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201115A Division AU2025201115A1 (en) 2017-08-14 2025-02-17 Method

Publications (1)

Publication Number Publication Date
AU2018316662A1 true AU2018316662A1 (en) 2020-02-20

Family

ID=63294371

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018316662A Abandoned AU2018316662A1 (en) 2017-08-14 2018-08-14 Method
AU2025201115A Pending AU2025201115A1 (en) 2017-08-14 2025-02-17 Method

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201115A Pending AU2025201115A1 (en) 2017-08-14 2025-02-17 Method

Country Status (8)

Country Link
US (1) US20210093695A1 (enExample)
EP (1) EP3668535A1 (enExample)
JP (1) JP7419229B2 (enExample)
CN (1) CN111225681A (enExample)
AU (2) AU2018316662A1 (enExample)
CA (1) CA3072867A1 (enExample)
WO (1) WO2019034862A1 (enExample)
ZA (1) ZA202000882B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111983241B (zh) * 2020-09-04 2022-05-20 四川大学华西医院 诊断脑卒中认知障碍的蛋白标志物以及模型的训练方法
WO2023100758A1 (ja) * 2021-11-30 2023-06-08 国立大学法人京都大学 ペプチド含有組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO2009056833A2 (en) * 2007-10-31 2009-05-07 Apitope Technology (Bristol) Limited Composition
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201300683D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10759838B2 (en) * 2015-03-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

Also Published As

Publication number Publication date
WO2019034862A1 (en) 2019-02-21
CA3072867A1 (en) 2019-02-21
JP2020530846A (ja) 2020-10-29
JP7419229B2 (ja) 2024-01-22
ZA202000882B (en) 2023-08-30
US20210093695A1 (en) 2021-04-01
AU2025201115A1 (en) 2025-03-06
EP3668535A1 (en) 2020-06-24
CN111225681A (zh) 2020-06-02

Similar Documents

Publication Publication Date Title
AU2025201115A1 (en) Method
Rodriguez et al. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord
JP5361895B2 (ja) 組成物
JP2013100313A (ja) Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
EP3881859A1 (en) Methods and compositions for increasing neurogenesis and angiogenesis
Comi et al. The heritage of glatiramer acetate and its use in multiple sclerosis
JP7591017B2 (ja) 寛容原性ペプチドを用いた治療方法
Brun et al. Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies
JP2020519627A (ja) 神経保護および再ミエリン化のための可溶性ｃｄ２４の使用方法
JP2024520952A (ja) 免疫原性ペプチドを使用した改善された処置方法
AU2021297152A1 (en) Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
ES2370957T3 (es) Composiciones que comprenden péptidos de la proteína básica de la mielina y sus utilizaciones médicas.
HK40016470B (en) Therapeutic method using dose escalation protocol for tolerogenic peptides
HK40016470A (en) Therapeutic method using dose escalation protocol for tolerogenic peptides
TW201712027A (zh) 多肽組合物
HK1142803B (en) Compositions comprising myelin basic protein peptides and medical uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: WONG PHARMACEUTICALS (HANGZHOU) CO., LTD.

Free format text: FORMER APPLICANT(S): APITOPE TECHNOLOGY (BRISTOL) LIMITED

HB Alteration of name in register

Owner name: WORG PHARMACEUTICALS (HANGZHOU) CO., LTD.

Free format text: FORMER NAME(S): WONG PHARMACEUTICALS (HANGZHOU) CO., LTD.

HB Alteration of name in register

Owner name: WORG PHARMACEUTICALS (ZHEJIANG) CO., LTD.

Free format text: FORMER NAME(S): WORG PHARMACEUTICALS (HANGZHOU) CO., LTD.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted